Is Rimonabant a new anti smoking drug? Effects of Rimonabant in the Reduction of Major Cardiovascular Risk Factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in …

After two years on a drug that affects the pleasure center of the brain, obese patients had reason to feel good: Their bellies shrank, their cholesterol improved and their insulin levels moved toward normal, according to research presented …

Continuing on the theme of unexpected toxicity landmines, I wanted to take a look at a highly anticipated obesity drug from Sanofi. Rimonabant is a small molecule antagonist of the CB-1 receptor, and it’s been getting a lot of press …

Rimonabant has been developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as ‘the munchies’.
Specifications - Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity…

The promising preclinical findings with Acomplia (rimonabant) have been confirmed in a series of clinical studies, including pivotal phase III trials involving over 6,000 obese subjects that were carried out in both the US and Europe.

Two-year data from the phase …

Not surprisingly, the growing prevalence of obesity has stimulated the search for drugs to treat this condition. Various therapeutic strategies have been explored, including:

Serotonin and noradrenaline reuptake inhibitors (anorectic agents)
Lipase inhibitors
ß 3-adrenoreceptor agonists
Leptin agonists
Melanocortin-3 agonists

Sanofi-Aventis’ approach is completely different to …

Obesity is now the most common nutritional disorder in western industrialised countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from over consumption of fatty foods. Prevalence …

Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!